Bentracimab is under clinical development by Serb and currently in Pre-Registration for Bleeding And Clotting Disorders. According to GlobalData, Pre-Registration drugs for Bleeding And Clotting Disorders have an 89% phase transition success rate (PTSR) indication benchmark for progressing into Marketed. GlobalData’s report assesses how Bentracimab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Bentracimab overview
Bentracimab (PB-2452 (MEDI-2452)) is under development for the treatment of major bleeding event in patients who are on ticagrelor therapy. It is a novel recombinant human monoclonal antibody antigen-binding fragment. The drug candidate is administered intravenously. The drug candidate is an antidote of ticagrelor and specifically reverses the antiplatelet effects of ticagrelor. It is developed based on the Absci's technology AI based synthetic biology
platform.
Serb overview
Serb is a pharmaceutical company that develops, markets and distributes prescription medicines for therapeutic niches. The company provides products portfolio such as antidote of organophosphorus compounds, glucocorticoid, colouring agents, lead and mercury chelating agents, products for treatment of drug poisoning, hypothyroidism, and other derivatives. The company offers products in the fields of critical care, toxicology, ophthalmology, endocrinology and infectious diseases products. SERB provides products in the forms of capsules, tablets and injections. It develops its portfolio of niche specialist’s products through research and development to maintain availability of life-saving medicines and answer unmet medical needs. SERB is headquartered in Paris, France.
For a complete picture of Bentracimab’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
